ArticleCureus2025
Enhancing Postprandial Hyperglycemia Detection Sensitivity in Individuals With Impaired Glucose Tolerance by Incorporating 1,5-Anhydroglucitol Into Diagnostic Testing: A Multicenter and Prospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProspective multicenter trials evaluating the sensitivity of 1,5-anhydroglucitol (1,5-AG) for detecting postprandial hyperglycemia in individuals with impaired glucose tolerance during health checkups in regional Japanese cities are limited. This study aims to address this gap through a comprehensive investigation.
methodsSixty-two participants with glycated hemoglobin (HbA1c) levels of 5.6-6.5% underwent a 75 g oral glucose tolerance test. Our primary objective was to evaluate the sensitivity of 1,5-AG compared to HbA1c in detecting ≥180 mg/dL glucose levels after an hour. Secondary endpoints are the sensitivity and specificity of the detection of load hyperglycemia.
resultsThe area-under-the-curve analysis indicated that 1,5-AG was not more sensitive than HbA1c in detecting ≥180 mg/dL glucose levels (0.543 vs. 0.686, p = 0.236). However, combining 1,5-AG with fasting blood glucose (FBG: 27.8% vs. FBG + 1,5-AG: 72.2%, p = 0.004) or HbA1c (HbA1c: 44.4% vs. HbA1c + 1,5-AG: 72.2%, p = 0.042) improved the sensitivity of detecting glucose spikes, suggesting that 1,5-AG may be a valuable addition to standard screening protocols for reducing undetected postprandial hyperglycemia, a risk factor for diabetes and cardiovascular diseases.
conclusionThese findings support the potential of 1,5-AG as an early marker of postprandial hyperglycemia during routine health checks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.